RNA Therapeutics Investments – Global Funding Outlook of the Evolving State of RNA Medicines and Technologies

Webinar Panel:
Ivan Burkov, Partner, INKEF Capital
Kent Rogers, Partner, ARCH Venture Partners
Qing Zhang, Partner, LDV Partners

Moderator:
Rahul Khetan, VC Associate, UCB Ventures

With over 500 nucleic acid companies currently at pre-series A status, over 900 RNA therapeutics programs, and the number of clinical studies has doubled over the last five years, the RNA industry remains ripe for investment.

This webinar will give the RNA Leaders investor community a spotlight to share their insights on how the RNA investment landscape is evolving including:

• Which RNA modality ‘mRNA, ASO, siRNA/RNAi, Oligo, or Aptamers is most exciting currently and why?
• How are investors evaluating RNA technologies being developed to advancements in delivery and RNA design?
• How important is including AI/ML platforms with a Biotech for an investment prospect?
• How are investors working with RNA companies to back the industry and evaluate new data - including ‘The PolymeRAI$E’ biotech pitching opportunity in September